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Non-genotoxic carcinogens are substances that induce tumorigenesis by non-mutagenic mechanisms and
long term rodent bioassays are required to identify them. Recent studies have shown that transcription profil-
ing can be applied to develop early identifiers for long term phenotypes. In this study, we used rat liver
expression profiles from the NTP (National Toxicology Program, Research Triangle Park, USA) DrugMatrix
Database to construct a gene classifier that can distinguish between non-genotoxic carcinogens and other
chemicals. The model was based on short term exposure assays (3 days) and the training was limited to oxi-
dative stressors, peroxisome proliferators and hormone modulators. Validation of the predictor was per-
formed on independent toxicogenomic data (TG-GATEs, Toxicogenomics Project-Genomics Assisted
Toxicity Evaluation System, Osaka, Japan). To build our model we performed Random Forests together with
a recursive elimination algorithm (VarSelRF). Gene set enrichment analysis was employed for functional
interpretation. A total of 770 microarrays comprising 96 different compounds were analyzed and a predictor
of 54 genes was built. Prediction accuracy was 0.85 in the training set, 0.87 in the test set and increased with
increasing concentration in the validation set: 0.6 at low dose, 0.7 at medium doses and 0.81 at high doses.
Pathway analysis revealed gene prominence of cellular respiration, energy production and lipoprotein metab-
olism. The biggest target of toxicogenomics is accurately predict the toxicity of unknown drugs. In this analy-
sis, we presented a classifier that can predict non-genotoxic carcinogenicity by using short term exposure
assays. In this approach, dose level is critical when evaluating chemicals at early time points.
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INTRODUCTION
Carcinogens are a large group of substances, organic and
inorganic, that are directly involved in causing cancer.
According to their mode of action they can be categorized
as either genotoxic (GTX) or not genotoxic (NGTX). The
former induces specific mutations or chromosome aberra-
tions through direct interaction with DNA, usually by for-
mation of covalent bonds (1). Such alterations are detected
by a battery of tests (Ames test, chromosomal aberration,
micronucleus assays) that measures the integrity and the
structure of the DNA. Non-genotoxic drugs, on the other
hand, represents chemicals capable of producing tumori-
genesis by some secondary mechanism not directly related
to DNA damage (2). Their activities are so diverse, that it is
easier to define the properties they lack rather than the prop-
erties they possess. In general they are chemicals that do not
induce DNA repair, and are negative in in vivo and in vitro
tests for mutagenicity.
Non-genotoxic carcinogens have a wide variety of mech-
anisms of cancer induction including receptor mediated
endocrine modulation, non-receptor mediated endocrine
modulation, regenerative proliferation, oxidative stress, xeno-
biotic receptor activation, peroxisome proliferation, induc-
tion of inflammatory response and/or gap junction intercellular
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inhibition (3). Free radical production (particularly ROS) is
a common sub-mechanism enhanced by several non-geno-
toxic carcinogens. Basically, cellular damage is promoted
when the balance between pro and anti-oxidants is dis-
turbed and the oxidants are not properly neutralized.
The diverse mechanisms of action, the tissue specificity
and the lack of genotoxicity make non-genotoxic identifica-
tion a challenging task. Rodent bioassays are considered the
best available method for detecting such carcinogens. Risk
assessment is done combining data from bioassays, epide-
miological data, toxico-kinetic and disposition studies (3).
The rationale behind this approach is that many of the drugs
known to be carcinogens to humans are also carcinogens to
animals. Classical studies in rats involve exposures for peri-
ods that range from 13 to 14 weeks. However, a proportion
of chemicals are detected at the end of a 2 year period, mak-
ing the animal chronic exposure assay elaborate and costly
intensive.
A rapid and sensitive method for detecting hepatocarcino-
genicity in drug screening is a long sought target. Control of
gene transcription is the main regulatory mechanism of bio-
logical systems. Gene expression precedes protein synthe-
sis, cell proliferation and ultimately pathological modi-
fications. Therefore, it should be the most sensitive point to
detect early changes (4). The aim of this analysis was to
build a model that distinguishes non-genotoxic liver carcin-
ogens by using expression profiles from short term expo-
sure chemical treatments in rodents. Experimental data
were obtained from the toxicogenomic database DrugMa-
trixTM, The National Toxicology Program (U.S. Department
of Health and Human Services) and The Toxicogenomics
Project Genomics Assisted Toxicity Evaluation system
(TG-GATEs) (5,6).
MATERIALS AND METHODS
Experimental design and compounds. To evaluate
molecular profiles, public available data from the National
Table 1. Groups of chemicals for classification analysis
Drugs Analysis set
DrugMatrix
Non Genotoxic carcinogens (n = 9)
Carbon Tetrachloride (CCL4), Methapyrilene (MP), Cyproterone Acetate (CPA) Phenobarbital (PBT), Fenofibrate (FF),
Clofibrate (CFB), Bezafibrate (BF), Diethylstilbestrol (DES), Gemfibrozil (GFZ)
Genotoxic Carcinogens and non-hepatocarcinogens (n=9)
2-Acetylaminofluorene (2-AAF), 3-Methylcholanthrene (MCA), Albendazole (ALB), Doxorubicin (DOX), Ibuprofen
(IBF), 1-Naphthyl Isothiocyanate (ANIT), Methyl salicylate (MS), Amiodarone (AMI), Hydrazine (N2H4)
Training set
Non Genotoxic carcinogens (n = 4)
Clofibric Acid (CA), Carbamazepine (CBZ), Ethinylestradiol (EE), 17-methyltestosterone (MET)
Genotoxic carcinogens and non-hepatocarcinogens (n = 29)
Clotrimazole (CLOT), Nimesulide (NIM), Naproxen (NAP), Dexamethasone (DXM), Diclofenac (DFNa), Fluphenazine
(FP), Clomipramine (CMP), Erythromycin (ERM), Meloxicam (MLX), Stavudine (D4T), Promethazine (PMZ), Val-
proic acid (VPA), Allyl alcohol (AA), Troglitazone (TGZ), Methimazole (MTZ), 6-Mercaptopurine (MP), Pioglita-
zone (PGZ), Tamoxifen (TMX), Altretamine (HMM), Chlorambucil (CBC), Carmustine (BCNU), Aflatoxin b1
(AFB1), N-nitrosodiethylamine (NDEA), Raloxifene (RLX), Lomustine (LS), Safrole (SF), Mitomycin-c (MMC),
Streptozotocin (STZ), Cytarabine (ara-C)
Test set
Unknown (n = 26)
Aminoglutethimide (AG), Closantel (CLO), Tandutinib (MLN518), Clomiphene (CLM), Sulindac (SULIN), Proges-
terone (PR), Cinnarizine (CIN), nystatin (NYS), indomethacin (IM), catechol (CC), ketorolac (KET), Isoeugenol
(IEUG), Leflunomide (LEF), Finasteride (FIN), Danazol (DZ), Salicylamide (SA), Chloroxylenol (CXL), Balsalazide
(BZ), Crotamiton(CROT), Zileuton (ZL), Propylthiouracil (PTU), Rosiglitazone (RGZ), Carbimazole (CBZ), Keto-
conazole (KET), Modafinil (MO), Simvastatin (SIM)
Unknown/
TGGATE
Non Genotoxic carcinogens (n = 13)
Methyltestosterone (MTS), Monocrotaline (MCT), Ethinylestradiol (EE), Fenofibrate (FFB), Methapyrilene (MP),
Phenobarbital (PBT), Thioacetamide (TAA), Carbon tetrachloride (CCL4), Clofibrate (CFB), WY-14643 (WY),
Gemfibrozil (GFZ), Carbamazepine (CBZ), Acetamide (AAA)
Genotoxic carcinogens and non-hepatocarcinogens (n = 21)
Tamoxifen (TMX), Lomustine (LS), Colchicine (COL), Carboplatin (CBP), Acetamidofluorene (AAF), Doxorubicin
(DOX), Naphthyl isothiocyanate (ANIT), ketoconazole (KC), Tetracycline (TC), Erythromycin ethylsuccinate
(EME), Caffeine (CAF), Tannic acid (TAN), Promethazine (PMZ), Nimesulide (NIM), Ethanol (ETN), Gentamicin
(GMC), Acetaminophen (APAP), Amiodarone (AM), Aspirin (ASA), Diclofenac (DFNa), Allyl alcohol (AA)
Validation set
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Toxicological Program (NTP) was selected (GEO Acce-
sion number GSE57822). This entity performs pre-chronic
and two year studies in laboratory animals in order to assess
specific needs in toxicology, yielding the largest molecular
toxicology reference. Briefly, arrays corresponding to 77
chemicals and their respective controls were downloaded
from DrugMatrix (Table 1). Total data points were 363:
three repeats per treatment involved 231 arrays and every
treatment had 4 controls, in total 132 control arrays in 22
control groups. The Carcinogenic Potency Database was
used as a first option to label the chemicals (7). Each array
was obtained from test-compound treated and vehicle con-
Table 2. Class discrimination analysis by Random Forest in
DrugMatrix data
Chemicals
Dose level
(mg/mL)
Random Forest
classification
a
Training set (N = 18) Predicted class
NGTX
Carbon Tetrachloride (CCL4)
Methapyrilene (MT)
Cyproterone Acetate (CPA)
Phenobarbital (PBT)
Fenofibrate (FF)
Clofibrate (CFB)
Bezafibrate (BF)
Diethylstilbestrol (DES)
Gemfibrozil (GFB)
GTX
2-Acetylaminofluorene (2-AAF)
3-Methylcholanthrene (MCA)
Doxorubicin (DOXO)
Hydrazine (N2H4)
Non hepathocarcinogen
1-Naphthyl Isothiocyanate (ANIT)
Methyl salicylate (MS)
Albendazole (ALB)
Amiodarone (AMI)
Ibuprofen (IBF)
1175
0100
2500
0054
0215
0130
0617
0280
0700
0030
0300
0003
0045
0060
0444
0062
0147
0263
0(
*
)
NGTXC
NGTXC
NGTXC
NGTXC
NGTXC
NGTXC
NGTXC
NGTXC
0
0
0
0
0
0
0
0
0
Test set (n = 33)
NGTX
Clofibric Acid (CA)
Carbamazepine (CBZ)
Ethinylestradiol (EE)
17-Methyltestosterone (MET)
GTX
Aflatoxin b1 (AFB1)
Carmustine (BCNU)
Chlorambucil (CBC)
Cytarabine (ara-C)
Lomustine (LS)
Mitomycin-c (MMC)
N-nitrosodiethylamine (NDEA)
Raloxifene (RLX)
Safrole (SF)
Streptozotocin (STZ),
Tamoxifen (TMX)
0448
0490
1480
2000
0000.3
0016
0004.5
0487
0008.75
0001.7
0034
0650
0488
0138
064
NGTX
NGTX
NGTX
NGTX
0
0
0
0
0
0
0
0
0
0
0
Table 2. Continued
Chemicals
Dose level
(mg/mL)
Random Forest
classification
a
Non hepathocarcinogen
6-Mercaptopurine (MP)
Allyl alcohol (AA)
Altretamine (HMM)
Clomipramine (CMP)
Clotrimazole (CLOT)
Dexamethasone (DXM)
Diclofenac (DFNa)
Erythromycin (ERM)
Fluphenazine (FP)
Meloxicam (MLX)
Methimazole (MTZ)
Naproxen (NAP)
Nimesulide (NIM) 
Pioglitazone (PGZ)
Promethazine (PMZ)
Stavudine (D4T)
Troglitazone (TGZ)
Valproic acid (VPA)
0025
0032
0040
0115
0089
0150
0010
1500
0002.5
0033
0100
0010
0162
1500
0113
1400
1200
1340
0
0
0
0
NGTXC(
*
)
NGTXC(
*
)
0
0
0
0
0
0
0
0
0
NGTXC(*)
0
0
Unknown
Aminoglutethimide (AG)
Balsalazide (BZ)
Carbimazole (CBZ)
Catechol (CC)
Chloroxylenol (CXL)
Cinnarizine (CIN)
Clomiphene (CLM)
Closantel (CLO)
Crotamiton(CROT)
Danazol (DZ)
Finasteride (FIN)
Indomethacin (IM)
Isoeugenol (IEUG)
Ketoconazole (KET)
Ketorolac (KET)
Leflunomide (LEF)
MLN518 
Modafinil (MO)
Nystatin (NYS)
Progesterone (PR)
Propylthiouracil (PTU)
Rosiglitazone (RGZ)
Salicylamide (SA)
Simvastatin (SIM)
Sulindac (SULIN)
Zileuton (ZL)
0350
1100
0400
0195
1915
0750
0250
0022
0750
2000
0800
0012
1560
0227
0048
0060
0212
0325
0134
0164
0625
1800
1300
1200
0132
0450
NGTXC
0
0
0
0
0
0
0
NGTXC
0
NGTXC
0
0
0
0
0
0
NGTXC
0
0
Undb
NGTXC
0
NGTXC
0
0
Abbreviations: NGTXC, Non-genotoxic Carcinogen; GTX, Genotoxic
compound; NH, Non hepatocarcinogen; 0, Negative for NGTXC.
aResults based on the OOB classification.
bUndetermined.
*Misclassified.
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trol-treated male rats after 72 hr of exposure with daily dos-
ing (Sprangle-Drawley, 6~8 weeks old). Liver tissues (medial
lobe) from three rats per chemical was collected and sub-
mitted to array processing. More data on the original exper-
iments can be found in (8). Concentrations selected for each
compound are summarized in Table 2.
The validation set was extracted from The Toxicogenom-
ics Project Genomics Assisted Toxicity Evaluation system
(TG-GATEs) (ExpressArray E-MTAB-800), a large-scale
database of transcriptomics and pathology data useful for
predicting the toxicity of new chemical entities (6). We
downloaded data from rats exposed daily for 4 days at three
doses (low, middle and high). Four hundred and seven
arrays corresponding to 34 chemicals and their correspond-
ing controls were obtained. Table 1 shows selected drugs
and Table 3 their dose levels.
Data pre-processing. Complete “.CEL” files were down-
loaded from the National Toxicological Program, Depart-
ment of Health and Human Services (USA) and the National
Bioscience Database Centre (National Bioscience Database
Center, Tokyo, Japan). Files belonged to the Affymetrix
Rat Genome 230 2.0 GeneChip Array (Affymetrix, Santa
Clara, CA, USA). Preprocessing adjustments were performed
with Expression Console (Affymetrix). Additional infor-
mation and raw data from the public repositories can be found
at https://ntp.niehs.nih.gov/drugmatrix/index.html and http://
dbarchive.biosciencedbc. jp/en/open-tggates/download.html/.
Table 3. Random Forest classification of TG-GATE data according to dose level
Low dose Medium dose High dose
Samples Conc. (mg/mL) Predicted class Conc. (mg/mL) Predicted class Conc. (mg/mL) Predicted class
NGTXC
Acetamide
Carbamazepine
Carbon tetrachloride
Clofibrate
Ethinylestradiol
Fenofibrate
Gemfibrozil
Methapyrilene
Methyltestosterone
Monocrotaline
Phenobarbital
Thioacetamide
WY-14643
300
030
030
030
001
010
030
010
030
003
010
004.5
010
0(
*
)
0(
*
)
0(*)
0(
*
)
0(
*
)
0(*)
NGTX
0(
*
)
0(*)
0(
*
)
0(
*
)
0(*)
NGTX
1000
0100
0100
0100
0003
0100
0100
0030
0100
0010
0030
0015
0030
0(
*
)
0(
*
)
0(*)
0(
*
)
NGTX
NGTX
NGTX
0(
*
)
0(*)
0(
*
)
0(
*
)
NGTX
NGTX
0200
0300
0300
0300
0010
0100
0300
0100
0300
0030
0100
0045
0100
0(
*
)
NGTX
0(*)
NGTX
NGTX
NGTX
NGTX
0(
*
)
0(*)
0(
*
)
NGTX
NGTX
NGTX
GTX
Acetamidofluorene
Carboplatin
Colchicine
Doxorubicin
Lomustine
Naphthyl isothiocyanate
Tamoxifen
030
001
000.5
000.1
000.6
001.5
006
0
0
0
0
0
0
0
0100
0003
0001.5
0000.3
0002
0005
0020
0
0
0
0
0
0
0
0300
0010
0005
0001
0006
0015
0060
0
0
0
0
0
0
0
Non-Hepatocarcinogen
Acetaminophen
Allyl alcohol
Amiodarone
Aspirin
Caffeine
Diclofenac
Erythromycin ethylsuccinate
Ethanol
Gentamicin
Nimesulide
Promethazine
Tannic acid
Tetracycline
300
003
020
045
010
001
100
400
010
010
020
100
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0600
0010
0060
0150
0030
0003
0300
1200
0030
0030
0060
0300
0300
0
0
0
0
0
0
0
0
0
0
0
0
0
1000
0030
0200
0450
0100
0010
1000
4000
0100
0100
0200
1000
1000
0
0
0
0
0
0
0
0
0
0
0
0
0
*Misclassified.
Prediction of Non-Genotoxic Carcinogenicity by Toxicogenomics 293
Each array (CEL file) was preprocessed and background
corrected, normalized and summarized using RMA (Robust
Multiarray Average) using Expression Console (Affymet-
rix) and Bioconductor packages of the R software (Fred
Hutchinson Cancer Research Center, Seattle, USA) (9). For
probe filtering, unspecific selection was carried out accord-
ing to the interquartile range (IQR) (cut off value according
to the IQR density plot).
Genes that had more than 1.5 fold increase/decrease rela-
tive to controls were chosen for further analysis. Addition-
ally, each drug treatment was compared with its respective
control using t test statistic. Results were further corrected for
multi-testing using the Benjamini & Yekutieli (2001) proce-
dure for (conservative) control of the false discovery rate
(FDR), with 0.05 as the significance level (10). Features that
met both criteria (t-test and 1.5 fold change) were combined
in a single list of differentially expressed genes that resulted
in 3778 probes that underwent classification analysis.
Class discrimination.
Feature selection by random forest: In order to dis-
criminate NGTX from other drugs (GTX and non-carcino-
gens) we divided the DrugMatrix data in a training set, a
test set, and an unclassified set. Data from (three) replicates
per treatment were treated individually, i.e. not combined.
The training set consisted of 18 compounds where half of
them were classical non-genotoxic carcinogens: oxidative
stressors, peroxisome proliferators and hormone modula-
tors. The test set consisted of 33 compounds, 4 NGTXC and
29 genotoxins or non-hepatocarcinogens. A third group was
built with DrugMatrix data: those with no conclusive data
about non-genotoxic hepatocarcinogenicity (n = 26). The
resulting groups are described in Table 1.
We used Random Forest (RF) for classification. Its per-
formance is comparable to other machine learning meth-
ods and combined with variable selection aggressively
reduces the set of genes (11). In this approach, training
and test sets are constructed internally and randomly, by
iteratively partition of the dataset. Many decision trees are
constructed (in this case 10,000 per RF). For the kth tree, a
random vector θk is created, independent of the other gen-
erated vectors but with the same distribution, and a tree is
grown casting a unit vote for the most popular class at
input x (12). 
Fig. 1. Principal Component Analysis (PCA) of differential expressed genes for DrugMatrix chemicals. Each compound was averaged
among replicates. Shapes indicate their class: circles correspond to non-genotoxic carcinogens, squares to genotoxins and triangles to
non-hepatocarcinogens.
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Table 4. High-scoring genes selected according to mean decrease accuracy
Affymetrix no Symbol Genename
1367696_at Ifitm2 Interferon induced transmembrane protein 2
1367780_at Pttg1 Pituitary tumor-transforming 1
1368205_at Cfi Complement factor I
1368260_at Aurkb Aurora kinase B
1368742_at C5ar1 Complement component 5a receptor 1
1368745_at Slc10a2 Solute carrier family 10 (sodium/bile acid cotransporter), member 2
1368860_at Phlda1 Pleckstrin homology-like domain, family A, member 1
1368991_at Smpd3 Sphingomyelin phosphodiesterase 3, neutral membrane
1369031_at Il18bp Interleukin 18 binding protein
1369161_at Abcb4 ATP-binding cassette, subfamily B (MDR/TAP), member 4
1369483_at Cd4 Cd4 molecule
1370166_at Sdc2 Syndecan 2
1370381_at Pnrc1 Proline-rich nuclear receptor coactivator 1
1370828_at Zdhhc2 Zinc finger, DHHC-type containing 2
1371170_a_at Il1a Interleukin 1 alpha
1371388_at Pdhb Pyruvate dehydrogenase (lipoamide) beta
1371577_at Ndufs1 NADH dehydrogenase (ubiquinone) Fe-S protein 1
1371754_at Slc25a25 Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 25
1371809_at Mrps18b Mitochondrial ribosomal protein S18B
1371893_at Col4a3bp Collagen, type IV, alpha 3 (Goodpasture antigen) binding protein
1371924_at Olfml3 Olfactomedin-like 3
1372013_at Ifitm1 Interferon induced transmembrane protein 1
1372044_at Tango2 Transport and golgi organization 2 homolog
1372920_at Prodh Proline dehydrogenase (oxidase) 1
1374061_at Cd302 CD302 molecule
1374537_at Chsy1 Chondroitin sulfate synthase 1
1374540_at Cdca7 Cell division cycle associated 7
1375861_at Nap1l5 Nucleosome assembly protein 1-like 5
1376135_at Dars2 Aspartyl-tRNA synthetase 2 (mitochondrial)
1377011_at Fry Furry homolog (Drosophila)
1377012_at Smarcad1 SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing 
DEAD/H box 1
1377785_at Dhx40 DEAH (Asp-Glu-Ala-His) box polypeptide 40
1379046_at Mlec Malectin
1379636_at Rmdn2 Regulator of microtubule dynamics 2
1380066_at Tfr2 Transferrin receptor 2
1381975_at Prune2 Prune homolog 2 (Drosophila)
1382078_at Tlr8 Toll-like receptor 8
1384240_at Agtr1a Angiotensin II receptor, type 1a
1385001_at Gsdmd Gasdermin D
1386080_at Hey1 Hes-related family bHLH transcription factor with YRPW motif 1
1387029_at Cfh Complement factor H
1387243_at Cyp1a2 Cytochrome P450, family 1, subfamily a, polypeptide 2
1387745_at Cd200r1 CD200 receptor 1
1388301_at Uqcrc1 Ubiquinol-cytochrome c reductase core protein I
1388460_at Capg Capping protein (actin filament), gelsolin-like
1389180_at Phkb Phosphorylase kinase, beta
1390426_at Notch1 Notch 1
1390667_at Lrrc51 Leucine rich repeat containing 51
1390839_at Pqlc3 PQ loop repeat containing 3
1391269_at Pim2 Pim-2 proto-oncogene, serine/threonine kinase
1392664_at Gpr182 G protein-coupled receptor 182
1392990_at Sox17 SRY (sex determining region Y)-box 17
1397317_at Itgb3 Integrin, beta 3
1399030_at Wdr45 WD repeat domain 45
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Random Forest parameters were set to: ntree = 10,000;
nodesize = 1; mtry = square root of number of genes. Once
obtained the forest, the construction of the classifier was
performed by a feature reduction algorithm, the backwards
variable elimination (VarSel package), where the less import-
ant features are successively eliminated and out of the bag
(OOB) error is continuously analyzed. The process fits ran-
dom forests iteratively in the training set, at each step dis-
carding the less important variables of previous models, but
keeping the OOB error until it drops substantially (fraction
dropped = 0.1). To evaluate stability of results and the pre-
diction error rate, bootstrap (.632+ rule) was run through all
the procedure (11,13). The reported error corresponded to
samples not used to fit the random forest or perform feature
reduction.
Pathway and gene analysis: Functional annotation
based on Gene Ontology was tested while accounting for
the topology of the GO graph. The methodology applied
Fisher’s exact test, which is based on gene counts. Each GO
category was tested independently, searching for overrepre-
sented terms within the group of differentially expressed
genes (14).
RESULTS
Pre-processing. After normalization and log transform-
ing the data, unspecific filtering was applied to the 31099
probes, leaving 10091 features. Differential expressed genes
were identified for each treatment when compared with the
set of corresponding controls by t-test and fold change. A
unique DEG list from all treatments consisting of 3778
probes was built. The filtered DrugMatrix set was used for
Principal Component Analysis (PCA). Fig. 1 shows a two-
dimensional plot of the data. Each color represents a single
compound defined by the rainbow pallet. Variance was rela-
tively low for the first four components: PCA1 (12%),
PCA2 (9%), PCA3 (8%), PCA4 (4%). Overall, there was
no significant clustering among NGTX and other com-
pounds, suggesting that further filtering steps were required
to make a successful discrimination.
Feature selection by random forest. Random Forests
analysis combined with a feature selecting algorithm was
used to build the predictor. In the training set, the out of the
bag error (OOB) for the initial random forest was 0.09
Fig. 2. Principal Component Analysis (PCA) performed with the 54 selected genes on the DrugMatrix set. Each compound was aver-
aged among replicates. Shapes indicate their class: circles correspond to non-genotoxic carcinogens, squares to genotoxins and trian-
gles to non-hepatocarcinogens. Note that non-genotoxic carcinogens (circles) clustered at the right of PC1, with the exception of CC4.
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(81.5% sensitivity, 100% specificity). Fifty four variables
were selected by variable selection without dropping the
OOB error substantially (Table 4). Fig. 2 shows a Principal
Component Analysis (PCA) constructed with the selected
genes as variables. Each compound was averaged among
replicates. The proportions of variance for the first three
components were: PC1 39%, PC2 12% and PC3 9%. As
can be seen on the plot, NGTX carcinogens were clustered
at the right of the PC1 axis, with the exception of Carbon
Tetrachloride. Fig. 3 represents the mean expression differ-
ence for each one of the predictor genes.
In order to assess an honest prediction of the error rate
from the training data we performed bootstrapping (0.632) in
which the random forest constructed for a certain number of
variables was subsampled and compared. The prediction
error rate among the bootstrap samples was 0.15 (Supple-
mental Fig. 1). Thirty genes were consistently selected (sta-
bility) in all the sub-samples (above 20%), with CYP1A2
being selected in 65%, Prodh in 32% and Itgb3 in 30%.
Prediction in the test set. The expression profiles of
the test sample group were run through the obtained random
forest. Overall, prediction error was lower than expected,
0.13. Sensitivity was 97% and specificity 81%. Three agents
were misclassified as NGTX carcinogens: Clotrimazole,
Stavudine and Dexamethasone. We found that six drugs had
similar profiles to our predictor in the unclassified group:
Aminoglutethimide, Crotamiton, Finasteride, Modafinil,
Rosiglitazone and Simvastatin. Table 2 shows the results of
the random forest in the DrugMatrix set.
Validation set. The performance of the classifier was
tested in an independent dataset. We applied the random
forest model to assess treated rat livers for 4 days and 34
drugs from the TG-GATE database. In contrast to DrugMa-
trix, three different doses were available at this time point
Fig. 3. Mean differential expression of the predictor genes in log2 scale. Black bars represent overexpressed genes; gray bars repre-
sent under-expressed genes.
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(low, middle and high). Prediction error varied significantly
among dose levels. While all concentration levels yielded
specificities of 100% (no false positives), sensitivity in-
creased from 10% at low doses and 38% at medium doses,
to 61% at high doses. Sensitivity could be increased at
expense of specificity. Areas under the curve (AUC) for the
ROC curve (Receiver Operating Characteristic) were 0.73
for low doses, 0.83 for middle doses and 0.87 for high
doses. The results of the classification model applied to the
validation set are described in Table 3.
Pathway analysis. In order to evaluate the biological
pathways involved in the expression of the 54 highest scor-
ing genes, we performed functional analysis of the GO terms
that were significantly represented. Differential expressed
genes were used as background list. We have found that sig-
nificant genes were scattered among diverse GO Biological
Process, most of them related to mitochondrial respiration,
energy production and lipoprotein metabolism. Detoxifica-
tion was located later in the list. Molecular functions
included several terms of signal transducing and receptor
activities. Table 5 shows the top eight GO annotations ac-
cording to Fisher’s exact test for BP (Biological Processes)
and MF (Molecular Functions). There is a representation of
how these terms are distributed over the GO graph in Sup-
plemental Fig. 2.
DISCUSSION
Toxicogenomics is defined as the application of genom-
ics technologies to study the adverse effects of pharmaceuti-
cal and environmental chemicals, with the hope of improving
risk assessment and hazard screening (5). In this paradigm,
public databases are essential tools for multiple actions,
such as comparing profiles, discovering patterns or integrat-
ing networks. The largest databases available to date are the
Japan Project Database (TG-GATE) and DrugMatrix (National
Toxicological Program, NTP, USA) (5,6). Their diversity
and standardized protocol make them the current reference.
In recent years other databases were made available (CBES,
CTD, etc.) and the challenge has been extended to data
mining (15).
The mechanisms of non-genotoxic carcinogenicity are
well described, although not well understood. It is assumed
that most non-genotoxic carcinogens induce neoplasm and
exhibit threshold tumor dose-responses. Classically, NGTX
are regarded as tumor promoters but mechanisms such as
regenerative hyperplasia, cytotoxicity or induction of oxida-
tive damage are also key events for tumor initiation (16).
There is still uncertainty whether NGTX are capable of ini-
tiate tumor events by themselves or whether they need coin-
cidental factors. In this study, we focused our efforts to
rodent hepatocarcinogens, a common target of safety assess-
ment in drug development.
One of the most, if not the most, important step in class
prediction is the correct assignment of the training set. New
experimental data may change the status of a substance to
another category limiting applicability of the predictor.
Generalization of data is also critical, and in agreement with
previous studies, false positives are often difficult to avoid
(or “unavoidable”). In order to evaluate a complex process
like carcinogenesis, we have selected compounds with three
Table 5. Top GO terms of enriched analysis according to Fisher’s exact test
Biological
process
Term Annotated Significant Expected F. classic
GO:0045333 Cellular respiration 028 5 0.42 4.8e-05
GO:0015980 Energy derivation by oxidation of organic compounds 050 6 0.75 8.3e-05
GO:0014823 Response to activity 023 4 0.35 0.00033
GO:0007507 Heart development 124 8 1.87 0.00043
GO:0006091 Generation of precursor metabolites and energy 068 6 1.03 0.00046
GO:0042157 Lipoprotein metabolic process 029 4 0.44 0.00082
GO:0051701 Interaction with host 030 4 0.45 0.00094
GO:0006869 Lipid transport 079 6 1.19 0.00104
Molecular
function
GO:0004872 Receptor activity 172 8 2.30 0.0016
GO:0008528 G-protein coupled peptide receptor activity 020 3 0.27 0.0022
GO:0001653 Peptide receptor activity 021 3 0.28 0.0025
GO:0060089 Molecular transducer activity 215 8 2.88 0.0066
GO:0001948 Glycoprotein binding 031 3 0.42 0.0077
GO:0038024 Cargo receptor activity 011 2 0.15 0.0089
GO:0005319 Lipid transporter activity 035 3 0.47 0.0109
GO:0004930 G-protein coupled receptor activity 049 3 0.66 0.0269
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modes of action to train our model: oxidative stressors, per-
oxisome proliferators and hormone modulators. Our hypothe-
sis was that in some point, similarities among gene profiles
would allow discrimination between non-genotoxic carcin-
ogens and other class of chemicals.
We chose Random Forest as our machine learning method
because is a robust classification algorithm. Feature reduc-
tion was performed by recursive variable elimination while
maintaining class error (11). We report a predictor of 54
variables, a number that may be reduced to 24 without los-
ing much prediction accuracy. After training the model, we
applied our classifier to the DrugMatrix test set, which
resulted in a relatively low total error. Only three false posi-
tives were detected and no false negatives among the OOB
samples. The small sample size could explain why the pre-
diction error of the test set was lower than the estimation of
the training set (0.13). It is interesting that prediction accu-
racy increased with increasing doses in the validation set.
This behavior could be explained by the fact that DrugMa-
trix doses for 3 day treatments were higher than TG-GATE
in almost all compounds, frequently several times higher
than the therapeutic dose.
One of the false positives detected was clotrimazole
(CTL), an imidazole antimitotic. It is an inhibitor of p450,
blocker of intracellular Ca++ stores and activator of the
xenobiotic response (17). It has important correlation with
our predictor, particularly in the induction of ZDHHC2
(Palmitoyltransferase ZDHHC2), a protein responsible for
membrane binding and protein localization (receptors).
Imidazole agents modulate p450 response by different gene
subfamilies and display different actions (18). The other
two miss-classified drugs were Dexamethasone (DXM) and
Stavudine (d4T). When compared to our predictor, we found
proximity in genes related to stress and inflammation (Cyp1a2,
IL1A, COL4A3BP, SDC2, PTTG1, C5ar1, CFH, Cfi).
In line with previous studies, a mechanistic approach is a
promising strategy for prediction as well as for pathway or
functional category analysis. In this study, the most signifi-
cant biological processes comprised those related to cellu-
lar respiration, energy derivation by oxidation of organic
compounds and generation of precursor metabolites. This
observation is in agreement with the known action of non-
genotoxins and the role oxidative stress in carcinogenesis
(3,19). Additionally, the presence of genes related to lipid
metabolism is typical of profiles delivered by peroxisome
proliferators. Others genes involved complement cascade,
inflammation response, and some of them were related to
cellular attachment.
Our signature included synthetic sex steroids (cyperone
acetate, 17-methyltestosterone, diethylstilbestrol and ethinyl-
estradiol). Several of them were shown to produce liver
tumors in rats when given at therapeutic doses (20). Ini-
tially, the non-genotoxic effects of steroids were thought to
be triggered by downstream genes of specific receptors, al-
though increasing data suggest that they possess genotoxic
action as well. We decided to keep them as NGTX carcino-
gens because the effect was complementary. Increased CYP
activities and alterations in sterol metabolism are frequently
associated with hepatomegaly in a non-genotoxic manner
(3).
A steroid responsive gene, Interleukin-1a (IL-1a), is a
high scoring gene in our signature. It is a critical cytokine
whose expression is related with various aspects of human
reproduction and expressed in a number of solid tumors. IL-
1a serves as attractant by lymphocytes that keep the inflam-
mation state that precedes malignancy. Sex steroid recep-
tors downregulate and confine IL-1a expression, but its
deregulation is a key inducer of proteolytic enzymes that
degrade the extracellular matrix and remodel tissue (21).
Several studies have provided gene predictors for non-
gentoxic hepato-carcinogens (22-28). Most of the method-
ologies used were based on support vector machines (SVM)
coupled with a feature reduction algorithm. Published gene
classifiers ranged from 9 to more than 100 probes and pre-
diction accuracies were roughly equivalent. In general, data
from rats under longer exposures provided higher accura-
cies. The composition of predictors differed among studies
in length and diversity and only few genes overlapped. The
reason for such heterogeneity is given by the differences in
experimental designs. However, all these factors make bio-
logical interpretability more complex.
A recent study developed by Gusenleitner et al. (2014)
scanned most of the NTP database and built a classifier that
englobed liver carcinogenesis (combining both genotoxic
and non-genotoxic carcinogens) (29). They validated their
model with TG-GATE liver data and estimated liver car-
cinogenesis with an AUC of 0.78 (56.8% sensitivity and
82.91% specificity). It is interesting that our signature, al-
though confined to a non-genotoxic subgroup of short term
exposure, had in common CYP1a2 and ZDHHC2 as high
scoring genes. Also, the presence of members of the super-
family of solute carrier proteins (SCL genes) in both signa-
tures indicates the importance that membrane transporters
have for drugs that “hitch-hike” one or another to enter the
cells (30). On the other hand, the inclusion of genotoxic
compounds to predict global carcinogenesis resulted in a
signature with several cell cycle control genes, essential to
the regulation of growth and apoptosis during mutagenic
stress.
Toxicogenomics is a promising field with the hope of aid
both the earlier elimination of toxic compounds in the drug
pipeline and the discovery of new toxicity mechanisms. The
biggest target is accurately predict the toxicity of unknown
drugs. In this analysis, we presented a classifier that can
predict non-genotoxic carcinogenicity by using short term
exposure treatments from the NTP database. Although we
are aware that the classifier does not have the prediction
accuracy of signatures of long term exposure, early screen-
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ing is an advantage that would allow prioritizing com-
pounds for further testing.
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